Ivermectin kills scabies mites by paralyzing them. The drug forces open chloride channels in the mite’s nerve and muscle cells, flooding them with ions until the mite can no longer move, feed, or reproduce, and it dies. A standard oral dose of 200 micrograms per kilogram of body weight reaches effective blood levels within about four hours, and within a day of taking it, viable adult mites on the skin are essentially eliminated. The fuller picture, though, is more complicated than that one-day window suggests, because ivermectin’s relationship with the scabies life cycle determines whether a single dose is enough or whether you need a second round.
How Ivermectin Paralyzes and Kills the Mite
Scabies mites have chloride channels gated by glutamate and GABA, neurotransmitters that normally regulate nerve signaling. Ivermectin locks these channels in their open position, causing a continuous flood of chloride ions into the nerve and muscle cells. That sustained influx hyperpolarizes the cells, which is a fancy way of saying the electrical signal that drives movement flatlines. The mite becomes paralyzed and eventually dies.
1PubMed Central. Escalating Threat of Drug-Resistant Human Scabies: Current Insights and Future DirectionsThis mechanism is selective in an important way: mammals do not have the same glutamate-gated chloride channels that arthropods do, which is why the drug can be lethal to mites at doses that are safe for humans. Ivermectin is absorbed through the gut, circulates in the bloodstream, and reaches the mite through the skin tissue and plasma it feeds on. The drug’s half-life is roughly 18 hours, so blood concentrations drop fairly quickly after a single dose.
The Molting Problem and Why You Need Two Doses
If ivermectin kills adult mites so efficiently, why do doctors almost always prescribe a second dose a week or two later? The answer lies in the scabies life cycle. Female mites burrow into the outer layer of your skin and lay eggs. Those eggs hatch into larvae, which then go through several molts before becoming adults. Each molt involves a period where the developing mite essentially shuts down inside a protective shell while its body reorganizes.
Research on molting mites exposed to ivermectin in the lab found that even at concentrations that killed all adult females within two hours, roughly a third of molting mites survived. At a lower concentration that still killed all adult females within seven hours, a similar proportion of molting mites pulled through. The difference between adult survival and molting-mite survival was striking and consistent across different drug concentrations.
2PLOS Neglected Tropical Diseases. Can ivermectin kill molting Sarcoptes scabiei?The practical consequence is that a single dose of ivermectin can wipe out the adults and active larvae but leave molting-stage mites alive. Those survivors finish their molt, emerge as the next life stage, and carry on the infestation. A second dose given after the mites have completed molting catches these survivors. The standard interval between doses is one to two weeks, timed to hit the mites after they have emerged from their molt but before they can lay a new round of eggs. Researchers have noted that this molting resistance, not just egg hatching, could explain treatment failures even after two properly timed doses.
3PubMed Central. Can ivermectin kill molting Sarcoptes scabiei? – Section: DiscussionHow Ivermectin Compares to Permethrin
Permethrin 5% cream is the other frontline scabies treatment, and the two are compared constantly in clinical research. The head-to-head data consistently show that permethrin has a slight edge in cure rates. A meta-analysis covering nearly 1,700 patients found that oral ivermectin had a treatment failure rate of about 14% compared to roughly 10% for topical permethrin.
4Journal of the American Academy of Dermatology. Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta-analysis of randomized controlled trials A more recent meta-analysis confirmed this pattern, finding ivermectin was associated with a lower probability of clinical cure and a higher risk of treatment failure compared with permethrin.
5PubMed Central. Comparative effectiveness of ivermectin versus permethrin for the treatment of scabies: an updated systematic review and meta-analysisThat said, the gap narrows with time and repeated dosing. One trial found that while permethrin had a much higher cure rate than oral ivermectin after the first week (about 75% versus 30%), by the third week, after a second round of treatment, all three groups (oral ivermectin, topical ivermectin, and permethrin) had reached essentially 99–100% cure rates.
6Indian Journal of Dermatology, Venereology and Leprology. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies Permethrin tends to work faster because it is applied directly to the skin where the mites live, creating a killing zone right at the source. Ivermectin has to travel through the bloodstream first, and its short half-life limits how long it maintains effective concentrations.
The real advantage of oral ivermectin is not raw efficacy but practicality. Permethrin cream needs to be applied head-to-toe (neck down in adults), left on for 8 to 14 hours, and then washed off. In large households, institutional settings like nursing homes, or communities where water access is limited, getting every person to apply cream correctly is a logistical challenge. A pill is far simpler. Studies of patient preferences have found that permethrin was generally seen as more comfortable and perceived to have fewer side effects, but it was less affordable than oral ivermectin and harder to use consistently, especially for large or low-income families.
7PubMed Central. Understanding Perceptions and Experiences on Acceptability of Oral Ivermectin, Topical Permethrin, and their Combination in the Treatment of Adult Filipino Patients with Scabies: A Multiple Case StudyTopical Ivermectin as a Third Option
Ivermectin also comes in a topical formulation, typically as a 1% cream or lotion. This approach combines the direct skin contact of permethrin with the pharmacology of ivermectin. In one study, two applications of topical ivermectin achieved a cure rate of about 63% at two weeks, rising to roughly 84% at four weeks after repeating treatment. At the four-week mark, topical ivermectin was as effective as permethrin 2.5% cream.
8PubMed. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% creamThe topical version sidesteps some of the oral form’s limitations. Because it is applied directly to the skin, it does not depend as much on blood circulation to reach the mites. It still requires the same full-body application that makes permethrin inconvenient, though, so it does not offer the compliance advantage of a pill. Topical ivermectin is most useful as an alternative when permethrin is unavailable or when a patient cannot take oral medication.
Side Effects and Safety
Ivermectin has a remarkably clean safety profile for scabies treatment. In a retrospective study of 360 patients, fewer than 2% reported any side effects that could be attributed to the drug. The reactions that did occur were mild: a couple of patients had increased itching during the first month, a couple had nausea and vomiting, and a few had diarrhea or abdominal pain.
9PubMed Central. Effect of ivermectin on scabies: a retrospective evaluation A comparison trial against lindane found that ivermectin’s side effects were mild and transient, with one case each of low blood pressure, abdominal pain, and vomiting.
10JAMA Dermatology. Equivalent Therapeutic Efficacy and Safety of Ivermectin and Lindane in the Treatment of Human ScabiesThis mild side-effect profile holds up even in mass treatment campaigns, where hundreds or thousands of people receive the drug at once. No serious adverse events have prevented patients from completing their treatment courses in the studies reviewed.
Children, Pregnant Women, and Other Special Cases
Ivermectin labeling traditionally advises against use in children weighing under 15 kilograms, but the evidence behind that restriction has been shifting. A multicenter study of 170 infants and young children weighing between 4 and 14.5 kilograms found that adverse events occurred in only 4% of patients, none were severe, and 85% achieved healing.
11British Journal of Dermatology. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study A pooled analysis of data from over 1,000 ivermectin-treated children under 15 kg found that about 1.4% experienced any adverse event at all, and none of those events were serious. All were mild, self-limiting, and resolved without additional treatment.
12PLOS Neglected Tropical Diseases. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?A phase 2 trial specifically studying ivermectin in children aged 2 to 4 years found that a single 3 mg dose achieved drug levels comparable to those seen in older children receiving the standard weight-based dose. About 91% of these young children had complete resolution of their scabies, and the few side effects that appeared (mostly mild stomach upset) did not require medical treatment.
13The Lancet Regional Health – Western Pacific. Ivermectin therapy for young children with scabies infection: a multicentre phase 2 non-randomized trialPregnancy is a more cautious area. A systematic review found that ivermectin exposure during pregnancy did not clearly increase the risk of spontaneous abortions, stillbirths, or congenital anomalies, but the certainty of evidence was rated very low.
14The Lancet. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis A separate review examining nearly 900 pregnancy outcomes in ivermectin-exposed women, including about 100 first-trimester exposures, did not find excessively abnormal birth outcomes compared with unexposed women.
15PubMed Central. Scabies-infested pregnant women: A critical therapeutic challenge Most guidelines still recommend permethrin as first-line for pregnant women, reserving ivermectin for cases where topical treatment has failed or is not feasible.
Why You Still Itch After Treatment
One of the most frustrating aspects of scabies treatment is that the itching often persists long after the mites are dead. This post-scabies itch is not a sign of treatment failure. It is a lingering immune reaction to dead mites, their eggs, and their fecal matter still sitting in your skin. Your body’s inflammatory response takes time to wind down even after the infestation is over.
Published guidance has traditionally said this residual itch lasts four to six weeks, but clinical data suggest it can go on considerably longer. A retrospective study found that post-scabies itch sometimes persisted for several months, required additional healthcare visits, and occasionally needed escalation to treatments like phototherapy or systemic anti-inflammatory drugs beyond simple topical steroids.
16PubMed Central. Management of common scabies and postscabetic itch in adults: Lessons learned from a single-center retrospective cohort study Post-scabies dermatitis, a hypersensitivity reaction to retained mite antigens, can even mimic active scabies closely enough to fool clinicians into prescribing unnecessary additional rounds of treatment.
17PubMed Central. Post-scabies Dermatitis Mimicking Treatment Failure: A Diagnostic ChallengeIf you are still itching two or three weeks after completing treatment and no new burrows are appearing, the treatment likely worked. Talk to your doctor about anti-itch strategies rather than reflexively retreating with more ivermectin or permethrin, since additional antiparasitic treatment will not help if the mites are already gone.
Crusted Scabies and Severe Infestations
Standard scabies involves a relatively small number of mites, typically just 10 to 15 on the entire body. Crusted scabies (sometimes called Norwegian scabies) is a different beast, involving thousands or even millions of mites in thick, crusted skin plaques. It tends to occur in people with compromised immune systems, elderly patients, and those in institutional care.
For crusted scabies, oral ivermectin alone is not enough. Treatment protocols combine multiple doses of ivermectin with topical scabicides and keratolytic agents (creams that soften and break down the thick crusts so the medication can actually reach the mites underneath). Patients with refractory crusted scabies have been treated with one to three doses of ivermectin at 14-day intervals, always alongside topical therapy.
18PubMed. Ivermectin for Sarcoptes scabiei hyperinfestation The mite burden in crusted scabies is so enormous that it creates a reservoir for reinfection and transmission, which is why these cases need aggressive, prolonged combination treatment.
Emerging Resistance
Ivermectin resistance in scabies mites was first documented in two patients with crusted scabies who had received 30 and 58 cumulative doses of ivermectin over four to four and a half years. Clinical and laboratory evidence showed their mites had developed resistance after that intensive use.
19Clinical Infectious Diseases. First Documentation of In Vivo and In Vitro Ivermectin Resistance in Sarcoptes scabieiThese were not isolated flukes. A decade-long study in scabies-endemic communities showed that mite survival times when exposed to ivermectin increased significantly from 1997 through 2006, and that trend remained significant even after excluding the known resistant patients.
20JAMA Dermatology. Longitudinal Evidence of Increasing In Vitro Tolerance of Scabies Mites to Ivermectin in Scabies-Endemic Communities The mechanisms likely involve changes to the chloride channels the drug targets, altered downstream signaling, and increased expression of drug-efflux proteins that pump ivermectin out of the mite’s cells before it can do its job.
1PubMed Central. Escalating Threat of Drug-Resistant Human Scabies: Current Insights and Future DirectionsResistance is still rare in typical scabies cases treated with one or two doses. The patients who developed it had received dozens of doses, usually for recurrent crusted scabies. But the trend of gradually increasing tolerance in community settings is worth watching, especially as mass drug administration programs expand.
Mass Drug Administration and Secondary Benefits
Ivermectin has found its biggest public health role not as an individual treatment but as a mass drug administration tool. In communities where scabies is endemic, treating everyone at once breaks the cycle of person-to-person reinfection that makes individual treatment so frustrating.
A landmark trial in the Solomon Islands compared three approaches across island communities. Standard care (treating only those with visible scabies) reduced prevalence by about half. Mass permethrin distribution reduced it by about 62%. But mass ivermectin distribution cut scabies prevalence by 94%, from about 32% down to under 2%.
21PubMed. Mass Drug Administration for Scabies Control in a Population with Endemic Disease A systematic review of mass drug administration programs overall found an average relative reduction in scabies prevalence of about 79%, rising to 85% in communities where baseline prevalence exceeded 10%.
22PubMed Central. Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysisBeyond scabies itself, these programs have yielded dramatic reductions in impetigo and other bacterial skin infections. Scabies burrows create entry points for bacteria like Streptococcus and Staphylococcus. In one community trial combining ivermectin with azithromycin, impetigo prevalence dropped by about 74% alongside the scabies reduction.
23PubMed Central. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial A Fiji-based program found that impetigo prevalence fell from about 15% to 6%, and hospitalizations for skin and soft tissue infections dropped by 17%.
24The Lancet Regional Health – Western Pacific. Prevention of bacterial complications of scabies using mass drug administration: A population-based, before-after trial in Fiji, 2018–2020 These bacterial complications of scabies can lead to serious downstream problems like kidney disease and rheumatic heart disease, so reducing them has health effects far beyond the itch.
Drug Interactions to Know About
Ivermectin is broken down in the body primarily by a liver enzyme called CYP3A4 and pumped out of cells by transport proteins. Other medications that interfere with these pathways can substantially change how much ivermectin your body is exposed to. Drugs that inhibit CYP3A4, like the antifungal ketoconazole, can roughly double ivermectin’s peak blood levels and triple the time the drug stays above effective concentrations.
25Scientific Reports. Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiaeThis means that if you are taking strong CYP3A4 inhibitors (certain antifungals, some HIV medications, grapefruit juice in large amounts), ivermectin blood levels could climb higher than expected, potentially increasing side effects. Conversely, drugs that speed up CYP3A4 activity (like the antibiotic rifampin or the seizure medication carbamazepine) could reduce ivermectin levels and make the treatment less effective. If you are on other medications, it is worth mentioning them to whoever prescribes your ivermectin.
26PubMed Central. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effectsCost and Access in Low-Resource Settings
In many parts of the world where scabies is most common, the cost and availability of treatment are as important as clinical efficacy. An economic evaluation from the Philippines found that oral ivermectin was cost-saving compared with permethrin from a patient’s out-of-pocket perspective, with lower total costs, slightly more cases cured, and greater health benefit per treatment course.
27PubMed Central. Economic Evaluation of Oral Ivermectin, Alone or in Combination with Permethrin, versus Permethrin, in the Treatment of Classic Scabies in the Philippine Setting A comparison across three treatment options (benzyl benzoate, permethrin, and ivermectin) found ivermectin to be the fastest regimen, achieving complete cure in two weeks while remaining among the most cost-effective options.
28PubMed Central. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabiesThe pill format also matters for distribution logistics. In remote communities with limited healthcare infrastructure, a supervised oral dose is far easier to deliver correctly than ensuring every person applies a cream head-to-toe, leaves it on overnight, and washes it off properly. That logistical reality is a large part of why ivermectin-based mass drug administration campaigns have been so successful at the population level even though permethrin outperforms it slightly in controlled clinical trials. Public health effectiveness depends on more than just pharmacology; it depends on whether people actually complete the treatment.